A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Ilodecakin (Primary) ; Capecitabine; Carboplatin; Cisplatin; Docetaxel; Fluorouracil; Folinic acid; Gemcitabine; Nivolumab; Oxaliplatin; Paclitaxel; Pazopanib; Pembrolizumab
  • Indications Breast cancer; Colorectal cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors ARMO Biosciences
  • Most Recent Events

    • 29 Jun 2017 Data (n=47) from this study published in an ARMO Biosciences Media Release.
    • 29 Jun 2017 According to an ARMO Biosciences media release, data from this study were presented at at the ESMO 19th World Congress on Gastrointestinal Cancer.
    • 06 Jun 2017 Results (n=29, data cut off; Nov 2016) assessing efficacy and safety in renal cancer patients presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top